GLUT1 deficiency syndrome: a case report with a novel SLC2A1 mutation

Nikola Ivančević*, Nataša Cerovac*, Blažo Nikolić*, Goran Ćuturilo†, Ana Marjanović‡, Marija Branković‡, Ivana Novaković‡

Univeristy of Belgrade, Faculty of Medicine, *Clinic of Neurology and Psychiatry for Children and Youth, †University Children's Hospital, ‡Clinic of Neurology, Belgrade, Serbia

Abstract

Introduction. GLUT1 deficiency syndrome (GLUT1 DS, OMIM 606777) is a metabolic brain disorder arising from mutations in SLC2A1 gene (chromosome 1) encoding glucose transporter type 1 located on blood-brain membrane. The “classic” phenotype in children includes early onset generalized farmacoresistant epilepsy, developmental delay, complex movement disorders and acquired microcephaly. However, there are milder phenotypes without epilepsy which could be seen in older children. The ketogenic diet is a treatment of choice. Case report. We present a four-year-old female patient with farmacoresistant generalized epilepsy, paroxysmal dystonic posturing, ataxia, hypotonia, developmental delay (motor, attention and speech disturbances), and microcephaly. The genetic testing revealed a novel point mutation at c.156T > A (p.Y52X) in exon 3 of SLC2A1 gene. The patient responded excellent on ketogenic diet. Conclusion. GLUT1 DS is treatable, and likely to be under-diagnosed neurological disorder. The ketogenic diet is resulting in good control of seizures in the patients, and it has certain benefit for the neurodevelopmental disability.

Key words: glut1 deficiency syndrome; diagnosis; diet ketogenic; treatment outcome.

Introduction

GLUT1 deficiency syndrome (GLUT1 DS, OMIM 606777) is a metabolic brain disorder arising from mutations in the neuronal glucose transporter GLUT1 (now designated SLC2A1) at short arm of chromosome 1 (1p35–31.3)1. GLUT1 located at the blood brain barrier is the main vehicle for glucose transport into the brain. The disease is caused by impaired D-glucose transport across the blood brain barrier, exposing the brain to the risk of energy failure.

The syndrome was first described by De Vivo et al. 2 (1991) in two children with early-onset epilepsy, developmental delay and acquired microcephaly. They had a low cerebrospinal fluid glucose concentration. GLUT1 DS is characterized by infantile onset refractory epilepsy, cognitive and motor develop-
mental delay, and mixed motor disorders including spasticity, ataxia and dystonia. Affected infants have neurodevelopmental impairment of variable severity and acquired microcephaly. Some patients have milder phenotypes and others have more severe with permanent neurological deficits. The cardinal biochemical feature is a decreased ratio of cerebrospinal fluid glucose relative to the plasma glucose concentration.

GLUT1 DS is caused by haploinsufficiency of SLC2A1 gene due to a de novo heterozygous mutation in a majority (90%) of cases. About 10% of patients have autosomal dominant inheritance and one affected parent, and only a few cases have autosomal recessive.

GLUT1 DS is a treatable disorder and a lot of patients, especially those with a mild phenotype, are likely to be under-diagnosed. The ketogenic diet is the mainstream of treatment, resulting in good control of seizures in most patients and it has certain benefit for the neurodevelopmental disability.

Case report

We presented a four-year-old female infant born at term by vaginal vertex delivery. There were no complications during pregnancy. Birth weight was 3 300 g and the 5-minutes Apgar score was 10. The physical examination at birth was without signs of abnormalities. Her parents were nonconsanguineous and healthy. Family history was unremarkable with no history of developmental problems, learning deficits, birth defects or genetic syndromes.

At the age of 6 months, the neurological examination revealed microcephaly, mild hypotonia, reduced motor activity, brisk deep tendon reflexes and developmental delay. The girl started to sit without support from the age of one year and to walk on a wide base, with support and with spastic-ataxic component from the age of two and a half years. She never attained the ability to walk. Speech development was also delayed. She had dysarthria with difficult understanding and very poor expressive speech. She was able to put words into phrases from the age of three years and her developmental quotient was 60. She had moderate intellectual impairment. Intensive physical and speech rehabilitation was performed.

First seizures were noticed starting from the age of 18 months with brief episodes of unresponsiveness, eye movements, head bobbing and hypotonia. The interictal electroencephalography (EEG) recording showed generalized spike and wave discharges with a frequency of 2.5–4 Hz. Antiepileptic therapy was given (valproate 30 mg/kg) and it resulted in exacerbation of seizures, so the drug was excluded. The seizures were also resistant to antiepileptic drugs clonazepam, clobasam and lamotrigine. Atypical absence seizures as the most common type of seizures were noticed at the age of three years and ethosuximide was introduced. The girl responded readily and better control of seizures was achieved. Later, levetiracetam was added with satisfactory results. The magnetic resonance imaging (MRI) of the brain done twice at the age of two and three years was normal. Metabolic investigations were within normal limits.

The genetic testing encompassed array comparative genomic hybridization (aCGH) and SLC2A1 gene sequencing. Normal result was obtained using aCGH, showing only one polymorphic copy number variant (loss of approx. 1.3 Mb at 15q11.2). Sanger sequencing of SLC2A1 gene disclosed variant c.156T > A (p.Y52X) in the exon 3 of the gene. This variant was not reported in the databases of The Exome Aggregation Consortium (ExAC), 1000 Genomes, and Human Gene Mutation Database (HGMD). The prediction analysis using the MutationTaster software indicated pathogenicity of the variant.

After the diagnosis of GLUT1 DS had been confirmed, the ketogenic diet (4 : 1 ratio) was introduced. Complete control of seizures was achieved. The girl is now 4 years old and shows delay in psychomotor development. She has microcephaly, abnormal gait (spastic-ataxic) and speech delay. She does not have seizures at all.

Discussion

Most patients with GLUT1 DS have perinatal history without complications, like in our reported patient. The neurological findings in the “classic” GLUT1 DS include epileptic encephalopathy, complex movement disorders (ataxia, dystonia, spasticity) and developmental delay including cognitive deficits. It also includes hypotonia and acquired microcephaly. Our patient showed all these characteristic features. In the literature, the average age for confirming diagnosis is 5 years and in our patient it was 4 years.

Recently, the “non-classic” clinical features of GLUT1 DS have included familiar and sporadic paroxysmal exercise-induced dyskinesia with or without epilepsy. It could also include varying degrees of cognitive deficits, dysarthria, dysfluency and expressive language deficits. Awareness of the broad range of potential clinical phenotypes associated with GLUT1 DS facilitates diagnosis. Post et al. listed the most frequent movement disorders as gait disturbances, dystonia, chorea, non-epileptic paroxysmal events, etc. Most patients have several types of movement disorders. Additionally, the syndrome of paroxysmal choreoathetosis with spasticity (DYT9), and paroxysmal exertional dyskinesia (DYT18) were also included as a part of clinical variability of GLUT1 DS.

The onset of seizures in GLUT1 DS occurs between 4 weeks and 18 months of age. In our patient the onset was at the age of 18 months. They include all seizure types (focal, generalized, absence and myoclonic) and are resistant to antiepileptic drugs. In our patient, atypical absence seizures were observed to be resistant to different drugs. They showed, however, good clinical response to etosuximide and levetiracetam. The EEG findings in our patient was also typical for this syndrome (generalized 2.5–4 Hz spike and wave discharges), while the neuroimaging findings were normal. In fact, the conventional anatomic neuroimaging with computed tomography (CT) or the MRI is typically normal in the patients with GLUT1 DS, whereas the metabolic imaging with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) reveals a distinctive pattern of

---

Ivančević N, et al. Vojnosanit Pregl 2019; 76(5): 543–546.
hypometabolism in the thalami and mesial temporal regions. It suggests impaired function of thalamo-cortical network as an important factor in epileptogenesis.

Certain antiepileptic drugs, like valproate, have the potential to exacerbate seizures and that happened to our patient. It is confirmed that valproate can significantly inhibit the GLUT1 function and glucose transport resulting in the increased seizure activity in the patient with GLUT1 DS. Therefore, it is important to be careful with the use of valproate in the patient with compromised function of GLUT1.

The ketogenic diet (high-fat, carbohydrate-restricted) plays an indispensable role in the treatment of GLUT1 DS. It mimics the metabolic state of fasting, providing ketone bodies, derived from the hepatic metabolism of fatty acid, as an alternative fuel source for the brain. Therefore, the ketogenic diet is a proven therapy for the treatment of seizures and other clinical features of the syndrome. This treatment in our patient resulted in subsequent improvement in her neurological status (gait, ataxia, spasticity) as well as cessation of seizures.

Our patient fulfilled the criteria for the “classic” phenotype of GLUT1 DS: epilepsy, developmental delay, cognitive deficit, microcephalia, hypotonia, spasticity and a complex movement disorder (ataxia, dystonia). The diagnosis in our patient was confirmed by identification of pathogenic nucleotide substitution in the exon 3 of the SLC2A1 gene.

The phenotype-genotype correlation is not well-established. The relationship between clinical and genetic characteristics is analyzed in one study. Sporadic cases with SLC2A1 de novo mutation (direct gene sequencing revealed missense, nonsense and splice site mutation) had a more severe phenotype than familiar cases (all patients presented with missense mutation). Sporadic cases had more profound cognitive disability, more severe form of epilepsy and neurologic deficits. The milder phenotype was observed in familiar cases in the form of “benign” epilepsy and slight movement disorder. Another study presented that missense mutations more frequently showed “mild” phenotype, which, of course, could be observed in a variety of other genetic disorders. However, the patients with the same mutation could show phenotypic variety, suggesting that other genes or other proteins are involved in glucose transport, pathophysiology of the disease and phenotype. It raises the unsolved question on the real incidence of GLUT1 DS, treatment with ketogenic diet in milder forms of disease and concerns about genetic counseling.

**Conclusion**

We presented the patient with GLUT1 DS, novel causative SCL2A1 gene variant and effective treatment with ketogenic diet. Although presentation was rather typical, diagnosis was confirmed at the age of 4 years which is in concordance with reports from other centers. It is well-established that early initiation of the ketogenic diet results in better seizure control and improves the neurologic outcome. One solution could be an employment of massive parallel gene sequencing in an early course of infantile seizures, which could provide timely diagnosis in a substantial proportion of patients.

**Acknowledgements**

This work was supported by the Serbian Ministry of Education, Science and Technological Development (Grant ON175091).

**REFERENCES**

1. Köpper J, Leinderscker B. GLUT1 deficiency syndrome-2007 update. Dev Med Child Neurol 2007; 49(9):707–16.
2. De Viro DC, Trifiletti RR, Jacobson RJ, Raunen GM, Belmond R-A, Harik SI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991; 325(10): 703–9.
3. Pearson TS, Akman C, Hinton VJ, Kristin E, De Viro DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1DS). Curr Neurol Neurosci Rep 2013; 13(4): 342.
4. Peng AW, Greary BR, Engeslak KM, Natamura A, Yang H, De Viro DC. Glucose transporter type 1 deficiency syndrome: epileptic phenotypes and outcomes. Epilepsia 2012; 53(9): 1503–10.
5. Köpper J, GLUT1 deficiency syndrome in clinic practise. Epilepsy Res 2012; 100(3): 272–7.
6. Beuschmann K. The expanding phenotype of GLUT1 deficiency syndrome. Brain Dev 2009; 31(7): 545–52.
7. Schneider S.A, Paiam-Ruiz C, Garcia-Gornatiaga J, Quinn NP, Weiner YG, Lentric H et al. GLUT1 gene mutations cause sporadic paroxysmal exercise-induced dyskinesias. Mov Disord 2009; 24(11): 1684–8.
8. Pazi R, Collina A, Rottman M, Engeslak K, De Viro DC. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord 2010; 25(3): 275–81.
9. Außerberger G, Ratzlaff T, Lanker A, Nelles HW, Leahu B, Bäkofzki F, et al. A gene for autosomal dominant paroxysmal chro- oatheatosis/spasticity (CSE) maps to the vicinity of a potas-

Ivančević N, et al. Vojnosanitetski Pregl 2019; 76(5): 543–546.
17. De Giorgis V, Tentonico F, Cereda C, Balottin U, Bianchi M, Giordano L, et al. Sporadic and familiar glut1ds Italian patients: a wide clinical variability. Seizure 2015; 24: 28–32.
18. Leen WG, Kröpper J, Verbeek MM, Leferink M, Hufste T, van Engelen BG, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 2010; 133(Pt 3): 655–70.
19. De Giorgis V, Veggiotti P. GLUT1 deficiency syndrome 2013; current state of the art. Seizure 2013; 22(10): 803–11.
20. Melnikova AM, Keif CM. Clinical variability of GLUT1DS. Seizure Disord 2015; 29(2): 14.

Received on April 06, 2017.
Accepted on July 07, 2017.
Online First September, 2017.